Medscape17h
Alzheimer Drug Donanemab Gets No-Go From European Regulator
The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...
European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
EU regulators block new Alzheimer’s drug citing potentially fatal side effects
The company behind the drug donanemab said it will ask regulators to reconsider the decision. View on euronews ...
Eli Lilly's Alzheimer's drug rejected in Europe
The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...
STAT20h
Eli Lilly’s Alzheimer’s drug gets thumbs-down from European regulators
Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say it shouldn't be approved.